RegeneRx

Shareholder letter - Tuesday February 17, 2015

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

February 25, 2015
RegeneRx Receives Israeli Patent for Treating and Repairing Heart Damage


February 19, 2015
RegeneRx Updates Website


February 17, 2015
RegeneRx Releases Letter to Shareholders


January 28, 2015
RegeneRx and G-treeBNT Create Joint Venture to Develop RGN-259 in the U.S.


December 29, 2014
RegeneRx Partner Submits Phase IIB/III IND to Korean Health Authority for RGN-259 for the Treatment of Dry Eye Syndrome


November 25, 2014
Researchers Report Thymosin Beta 4 is Cardioprotective in Pulmonary Hypertension/Heart Failure Model


November 6, 2014
RegeneRx Announces Management Changes